152 related articles for article (PubMed ID: 36895459)
1. Multi-Drug Resistance against Second-Line Medication and MicroRNA Plasma Level in Metastatic Breast Cancer Patients.
Dehghani M; Mokhtari S; Abidi H; Alipoor B; Nazer Mozaffari MA; Sadeghi H; Mahmoudi R; Nikseresht M
Iran J Med Sci; 2023 Mar; 48(2):146-155. PubMed ID: 36895459
[TBL] [Abstract][Full Text] [Related]
2. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
[TBL] [Abstract][Full Text] [Related]
3. Plasma microRNAs Predict Chemoresistance in Patients With Metastatic Breast Cancer.
Shao B; Wang X; Zhang L; Li D; Liu X; Song G; Cao H; Zhu J; Li H
Technol Cancer Res Treat; 2019 Jan; 18():1533033819828709. PubMed ID: 30786836
[TBL] [Abstract][Full Text] [Related]
4. MiR-199a-3p enhances breast cancer cell sensitivity to cisplatin by downregulating TFAM (TFAM).
Fan X; Zhou S; Zheng M; Deng X; Yi Y; Huang T
Biomed Pharmacother; 2017 Apr; 88():507-514. PubMed ID: 28126676
[TBL] [Abstract][Full Text] [Related]
5. Identification and clinical implications of circulating microRNAs for estrogen receptor-positive breast cancer.
Park IH; Kang JH; Lee KS; Nam S; Ro J; Kim JH
Tumour Biol; 2014 Dec; 35(12):12173-80. PubMed ID: 25179838
[TBL] [Abstract][Full Text] [Related]
6. Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.
Müller V; Gade S; Steinbach B; Loibl S; von Minckwitz G; Untch M; Schwedler K; Lübbe K; Schem C; Fasching PA; Mau C; Pantel K; Schwarzenbach H
Breast Cancer Res Treat; 2014 Aug; 147(1):61-8. PubMed ID: 25086636
[TBL] [Abstract][Full Text] [Related]
7. Association of circulating miR-21, -205, and -182 with response of luminal breast cancers to neoadjuvant FAC and AC treatment.
Chekhun VF; Borikun TV; Bazas VМ; Andriiv AV; Klyusov OМ; Yalovenko TМ; Lukianova NY
Exp Oncol; 2020 Sep; 42(3):162-166. PubMed ID: 32996748
[TBL] [Abstract][Full Text] [Related]
8. Circulating MiR-125b as a marker predicting chemoresistance in breast cancer.
Wang H; Tan G; Dong L; Cheng L; Li K; Wang Z; Luo H
PLoS One; 2012; 7(4):e34210. PubMed ID: 22523546
[TBL] [Abstract][Full Text] [Related]
9. Dynamics of circulating microRNAs as a novel indicator of clinical response to neoadjuvant chemotherapy in breast cancer.
Zhu W; Liu M; Fan Y; Ma F; Xu N; Xu B
Cancer Med; 2018 Sep; 7(9):4420-4433. PubMed ID: 30099860
[TBL] [Abstract][Full Text] [Related]
10. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.
Zhang Z; Zhang L; Yu G; Sun Z; Wang T; Tian X; Duan X; Zhang C
Cancer Chemother Pharmacol; 2020 Dec; 86(6):761-772. PubMed ID: 33068176
[TBL] [Abstract][Full Text] [Related]
11. Clinical Identification of Dysregulated Circulating microRNAs and Their Implication in Drug Response in Triple Negative Breast Cancer (TNBC) by Target Gene Network and Meta-Analysis.
Qattan A; Al-Tweigeri T; Alkhayal W; Suleman K; Tulbah A; Amer S
Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33918859
[TBL] [Abstract][Full Text] [Related]
12. Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in Resistance.
Rezaei Z; Sebzari A; Kordi-Tamandani DM; Dastjerdi K
DNA Cell Biol; 2019 Feb; 38(2):184-192. PubMed ID: 30702337
[TBL] [Abstract][Full Text] [Related]
13. Linc00518 Contributes to Multidrug Resistance Through Regulating the MiR-199a/MRP1 Axis in Breast Cancer.
Chang L; Hu Z; Zhou Z; Zhang H
Cell Physiol Biochem; 2018; 48(1):16-28. PubMed ID: 30001527
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
15. Circulating miRNA-199a and miRNA-122 Levels as Potential Diagnostic and Prognostic Biomarkers for Hepatocellular Carcinoma.
Wu J; Wu Y; Luo Y; Li X; Lin N; Yang X; Lin Y; Chen M
Ann Clin Lab Sci; 2020 Mar; 50(2):219-227. PubMed ID: 32366560
[TBL] [Abstract][Full Text] [Related]
16. High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer.
Anfossi S; Giordano A; Gao H; Cohen EN; Tin S; Wu Q; Garza RJ; Debeb BG; Alvarez RH; Valero V; Hortobagyi GN; Calin GA; Ueno NT; Woodward WA; Reuben JM
PLoS One; 2014; 9(1):e83113. PubMed ID: 24416156
[TBL] [Abstract][Full Text] [Related]
17. miR-199a-5p confers tumor-suppressive role in triple-negative breast cancer.
Chen J; Shin VY; Siu MT; Ho JC; Cheuk I; Kwong A
BMC Cancer; 2016 Nov; 16(1):887. PubMed ID: 27842518
[TBL] [Abstract][Full Text] [Related]
18. Circulating miR-34a and miR-125b as Promising non Invasive Biomarkers in Egyptian Locally Advanced Breast Cancer Patients.
Kassem NM; Makar WS; Kassem HA; Talima S; Tarek M; Hesham H; El-Desouky MA
Asian Pac J Cancer Prev; 2019 Sep; 20(9):2749-2755. PubMed ID: 31554373
[TBL] [Abstract][Full Text] [Related]
19. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients.
Jung EJ; Santarpia L; Kim J; Esteva FJ; Moretti E; Buzdar AU; Di Leo A; Le XF; Bast RC; Park ST; Pusztai L; Calin GA
Cancer; 2012 May; 118(10):2603-14. PubMed ID: 22370716
[TBL] [Abstract][Full Text] [Related]
20. High expression of microRNA-199a-5p is associated with superior clinical outcomes in patients with locally advanced rectal cancer.
Baek DW; Kim G; Kang BW; Kim HJ; Park SY; Park JS; Choi GS; Kang MK; Hur K; Kim JG
J Cancer Res Clin Oncol; 2020 Jan; 146(1):105-115. PubMed ID: 31781865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]